gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · TXGHealthcareLab Analytical Instruments

10x Genomics, Inc. Class A Common Stock (TXG)

$67.52+3.42%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$67.52▲ 405.39% in range
Nov 4, 2025Low $13.00 · High $97.74Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

10x Genomics closed at $67.52 on Nov 4, up 3.42%, 30.9% below its 52-week closing high. Volume of 2.9M shares was 0.76× its 20-day average (below normal).

Split-adjusted performance: -16.3% over one month, +196.9% over six months, +392.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $151.04M, down 12.6% from a year earlier, with a net margin of -11.9%.

Short interest was 12.7M shares at the Oct 15 settlement, down 17.2% from the prior report (10.9% of float, 2.6 days to cover).

Market cap$8.80B130.3M shares
Revenue · quarter$151.0M−12.6% YoY
Diluted EPS$-0.14−150.0% YoY
P/E · TTM—P/S 14.3×
Net margin-11.9%Gross 74.5%
Dividend yieldNone
52-week range13.00 – 97.74−30.9% from high
Volume2.9M0.76× 20-day avg
Volatility · 60d86.0%Annualised
Short % of float10.9%2.7 days to cover
Net cash$552.0MCash $552.0M
Next earnings—Not scheduled
Split-adjusted performance
1W −19.3%1M −16.3%3M +48.1%6M +196.9%YTD +314.0%1Y +392.8%3Y +88.9%5Y −57.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Lab Analytical Instruments

Percentile among 22 companies (100 = best)

6-month momentum100
Revenue growth16
Net margin57
Value (low P/E)—
Size62

Industry medians: 6-month return +33.8%, revenue growth +4.9%, net margin −19.0%, P/E 38.3×.

Short interest

Details →
Shares short12.7M−17.2% vs prior
Days to cover2.7Settled Oct 15
% of float10.9%
Short vol. 10d52.4%of daily volume

Closest peers by size in Lab Analytical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
TXG10x Genomics$67.52+3.42%+196.9%−12.6%−11.9%—$8.80B
BRKRBruker$63.79+12.90%+50.8%+5.2%−7.5%—$9.72BCompare
BIO.BBio-Rad Laboratories$379.50+4.22%—−0.1%57.1%45.6$10.15BCompare
BIOBio-Rad Laboratories$379.99+1.35%+46.7%−0.1%57.1%45.7$10.16BCompare
AVTRAvantor$15.65+0.38%+85.6%+4.6%12.0%31.4$10.60BCompare
RVTYRevvity$159.43−2.48%+60.9%+1.3%7.1%74.9$17.79BCompare
ILMNIllumina$226.54−4.90%+58.9%+4.2%19.5%38.3$34.25BCompare
MTDMettler-Toledo International$1,723.24+1.48%+29.9%+4.5%22.7%38.1$34.53BCompare
ALMRAlamar Biosciences$27.39−9.36%——−44.9%—$1.90BCompare

News about 10x Genomics

All news →
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker ResearchZacks Investment Research · Oct 8, 2026▲ Positive10x Genomics Begins Atera Shipments as Spatial Biology Demand RisesZacks Investment Research · Sep 30, 2026▲ PositiveTXG Stock Down Despite Patent Verdict Win Against Parse BiosciencesZacks Investment Research · Aug 31, 2026▲ PositiveThis $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116%The Motley Fool · May 12, 2026▲ Positive

Quick answers

What does 10x Genomics do?
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems.
What is TXG's market cap?
$8.80B, based on the Nov 4 close of $67.52.
Does 10x Genomics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of TXG is sold short?
12.7M shares, 10.9% of float, as of Oct 15, 2026.
What sector is TXG in?
Healthcare, in the Lab Analytical Instruments industry.

About 10x Genomics

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

HQ: Pleasanton, CA1,178 employeesListed Sep 12, 201910xgenomics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology